KIG
CLLS

Kowal Investment Group’s Cellectis CLLS Stock Holding History

Kowal Investment Group’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed – – 277
2021
Q3 		$0 Buy
+2
New +$28 ﹤0.01% 928

Other funds holding CLLS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Kowal Investment Group's CLLS Position: Q4 2021 in Review

Kowal Investment Group sold out of Cellectis (CLLS) in Q4 2021, closing a stake of 2 shares.

Kowal Investment Group first reported a position in CLLS in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 57 funds tracked by Wall St. Rank hold CLLS as of Q4 2021.

  • Kowal Investment Group reported no remaining Cellectis position as of Q4 2021 after selling out during the quarter.
  • Kowal Investment Group sold 2 Cellectis shares in Q4 2021.
  • Kowal Investment Group first reported a position in Cellectis in Q3 2021 and held it in 1 quarter.
  • Kowal Investment Group's Cellectis position peaked at $0 in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Cellectis as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.